Kamada Ltd. (KMDA)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$8.00−3.73%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $462M
- P/E (trailing)
- 21.1
- Forward P/E
- 13.9
- Dividend yield
- 2.1%
- 52-week range
- $6.50 – $9.35
- 52-week change
- +24.96%
- EPS (trailing)
- $0.38
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 9, 2026
About Kamada Ltd.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.
Headquarters: Rehovot, Israel · 462 employees · kamada.com